Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Hematologic Cancer Clinical Trials

A listing of Hematologic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (173) clinical trials

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of ...

Phase

The purpose of this study is to see if GS-9073 can benefit people with CLL. This study will also investigate the safety of GS-9973 and how weel the drug is tolerated.

Phase

The trial objectives will be evaluated in adult patients with histologically or cytologically documented NSCLC that is metastatic or recurrent and whose tumor tissue PD-L1 expression 0-49%. Sponsor recommends use of PD-L1 IHC 22C3 pharmDx assay. To compare the efficacy of AM0010 in combination with nivolumab vs. nivolumab alone as measured ...

Phase N/A

Prophylactic Early PN in HPT/BMT

A standard parenteral nutrition solution will be used. The parenteral nutrition solution will be given once daily, and infused intravenously. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L). Nutritional targets will be measured using indirect Calorimetry where available, or ...

Phase N/A

Safety of Romiplostim (Nplate ) Following UCBT

This is a single institution, phase I dose escalation study of weekly romiplostim post umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by day +30. Engraftment is defined as a platelet count 20 x 109/L on 3 consecutive measurements without transfusion for 7 days. Romiplostim is ...

Phase

T Cell Therapy for Adenovirus in Immunocompromised Patients

CTL Administration: If you are found to be eligible to take part in this study, you will receive the CTLs by vein (also called an infusion) over about 30 minutes. You will stay in the clinic for about 1 hour after the CTL infusion so that you can be checked ...

Phase

Protocol For A Research Database For Hematopoietic Stem Cell Transplantation Other Cellular Therapies and Marrow Toxic Injuries

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives To learn ...

Phase N/A

Study of EDO-S101 A First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

EDO-S101 is a new chemical entity, a first-in-class fusion molecule of an alkylator, bendamustine and a histone-deacetylase inhibitor (HDACi), vorinostat. It is anticipated that EDO-S101 may have activity in various hematological malignancies and solid tumors. This phase 1 study will enroll patients with various hematological malignancies. The study consists of ...

Phase

Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease

MESENCHYMAL STROMAL CELLS (MSC) have shown promising albeit not always consistent therapeutic effects in the treatment of severe steroid-resistant acute Graf versus Host Disease. Remarkably, in all reported clinical studies the toxicity of Mesenchymal stromal cells administration has been found consistently negligible. The investigators believe that Umbilical Cord (UC) derived ...

Phase

Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients

According to sample size calculation 30 newly diagnosed hematologic malignant patients and 30 healthy individuals will be included. Before treatment submaximal exercise capacity, physical activity, quality of life, pulmonary functions, respiratory and peripheral muscle strength, respiratory muscle endurance, dyspnea and fatigue perception, anxiety and depression will be evaluated. Primary outcome ...

Phase N/A